Literature DB >> 2833343

Clinical evaluation of cryosurgery in the treatment of primary liver cancer. Report of 60 cases.

X D Zhou1, Z Y Tang, Y Q Yu, Z C Ma.   

Abstract

Cryosurgery with liquid nitrogen was employed for the treatment of 60 patients with primary liver cancer (PLC) at the Liver Cancer Research Unit, Zhong Shan Hospital, Shanghai Medical University, the People's Republic of China, from November 1973 to August 1987. Of 60 patients, subclinical stage amounted to 35% (21/60), moderate stage 55% (33/60) and late stage 10% (6/60). There were 21 cases with small PLC (less than or equal to 5 cm). The postoperative course was uneventful in all of the 60 patients. These was no operative mortality, and there was no complications such as rupture of tumor, secondary bleeding, bile leakage, or abdominal infection. The 1-year, 2-year, 3-year, 4-year, and 5-year survival rates were 51.7% (30/58), 33.9% (19/56), 20.8% (11/53), 15.6% (7/45), and 11.4% (5/44), respectively, for the whole series. Among the 21 patients with tumor nodules less than or equal to 5 cm in diameter, the 1-year, 2-year, 3-year, 4-year, and 5-year survival rates were 76.2% (16/21), 61.9% (13/21), 50.0% (9/18), 41.2% (7/17), and 37.5% (6/16), respectively. These results indicate that hepatic cryosurgery is a promising, safe, and simple treatment for neoplastic disease of liver. Cryosurgery with liquid nitrogen can be considered the surgery of choice for nonresectable PLC in patients without jaundice, ascites, and noncompensated liver function, and the whole tumor mass can be involved in the frozen area.

Entities:  

Mesh:

Year:  1988        PMID: 2833343     DOI: 10.1002/1097-0142(19880501)61:9<1889::aid-cncr2820610928>3.0.co;2-w

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  23 in total

Review 1.  Cryosurgery in the treatment of liver metastasis from colorectal cancer.

Authors:  T S Ravikumar; R Sotomayor; R Goel
Journal:  J Gastrointest Surg       Date:  1997 Sep-Oct       Impact factor: 3.452

2.  Recurrence after resection of alpha-fetoprotein-positive hepatocellular carcinoma.

Authors:  X D Zhou; Z Y Tang; Y Q Yu; B H Yang; J Z Lu; Z Y Lin; Z C Ma; B H Zhang
Journal:  J Cancer Res Clin Oncol       Date:  1994       Impact factor: 4.553

3.  The treatment of primary and metastatic hepatic neoplasms using percutaneous cryotherapy.

Authors:  Mitchell T Smith; Charles E Ray
Journal:  Semin Intervent Radiol       Date:  2006-03       Impact factor: 1.513

4.  Hepatic cryosurgery for liver metastases. Long-term follow-up.

Authors:  N N Korpan
Journal:  Ann Surg       Date:  1997-02       Impact factor: 12.969

5.  Treatment of hepatic metastases by cryotherapy and regional cytotoxic perfusion.

Authors:  D L Morris; M D Horton; A V Dilley; A Warlters; P R Clingan
Journal:  Gut       Date:  1993-09       Impact factor: 23.059

6.  Clinical short-term results of radiofrequency ablation in liver cancers.

Authors:  Hong-Chi Jiang; Lian-Xin Liu; Da-Xun Piao; Jun Xu; Min Zheng; An-Long Zhu; Shu-Yi Qi; Wei-Hui Zhang; Lin-Feng Wu
Journal:  World J Gastroenterol       Date:  2002-08       Impact factor: 5.742

7.  [Cryotherapy of liver metastases. Initial results].

Authors:  T Junginger; J K Seifert; T F Weigel; A Heintz; K F Kreitner; C D Gerharz
Journal:  Med Klin (Munich)       Date:  1998-09-15

8.  Percutaneous cryoablation in combination with ethanol injection for unresectable hepatocellular carcinoma.

Authors:  Ke-Cheng Xu; Li-Zhi Niu; Wei-Bin He; Zi-Qian Guo; Yi-Ze Hu; Jian-Sheng Zuo
Journal:  World J Gastroenterol       Date:  2003-12       Impact factor: 5.742

9.  The role of cryosurgery in the treatment of hepatic cancer: a report of 113 cases.

Authors:  X D Zhou; Z Y Tang; Y Q Yu; J M Weng; Z C Ma; B H Zhang; Y X Zheng
Journal:  J Cancer Res Clin Oncol       Date:  1993       Impact factor: 4.553

10.  Adjuvant lipiodol I-131 after curative resection/ablation of hepatocellular carcinoma.

Authors:  K M Ng; R Niu; T D Yan; J Zhao; E McKay; F C K Chu; D L Morris
Journal:  HPB (Oxford)       Date:  2008       Impact factor: 3.647

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.